HOME >> MEDICINE >> NEWS
FDA approves Pfizer's Lyrica for the treatment of the two most common forms of neuropathic pain

NEW YORK, December 31, 2004 - Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market LyricaTM (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.

Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.

"Lyrica is an important new therapy for millions of people suffering from the two most common neuropathic pain conditions as it provides rapid and sustained pain relief," said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. "Lyrica also represents a major achievement in Pfizer's research program and confirms our leadership in bringing life-changing medicines to patients."

Neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from underlying conditions, such as diabetes or shingles. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy over the course of their disease and about one in six diabetes patients will experience painful diabetic neuropathy. The pain of DPN is often described as burning, tingling, sharp, stabbing, or pins and needles in the feet, legs, hands or arms.

PHN is a complication of shingles, a painful outbreak of rash or blisters on the skin caused by a reactivation of the same virus that causes chicken pox. Each year, about 150,000 Americans develop PHN, which is often characterized as constant stabbing, burning, or electric shock-like sensation.

The efficacy of Lyrica was established in six double-blind, placebo-controlled trials, three involving patients with DPN and three involving patients with
'"/>

Contact: Rebecca Hamm
212-733-8811
Burson-Marsteller
7-Jan-2005


Page: 1 2

Related medicine news :

1. FDA approves Enablex for treatment of overactive bladder
2. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
3. FDA approves Adderall XR (R) to treat ADHD in adults
4. FDA approves EPZICOM
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... Providing ... not understand the estate planning process, or where to even begin. “Now more than ... if you are to properly protect yourself and your family,” said attorney Lisa Edgar ...
(Date:4/21/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... a global crisis with solution to peace plan. Yisrayl says war has never brought peace ... given by the Creator Himself. , Yisrayl says war drums are beating all over ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... are five common elements between the Obamacare program that most Republicans love to ... uses Warfarin poison to kill hogs. , Like Obamacare, the Miller program ...
(Date:4/21/2017)... , ... April 21, 2017 , ... National pest management ... in the number of bed bug infestations over the 5-year period. In 2015 10% ... from the treatment of bed bug infested properties. , The health and economic consequences ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
Cached News: